←
Pereira Lab665 posts
Pereira Lab avatar

Pereira Lab

@CellReproLab

Cell Reprogramming in Hematopoiesis and Immunity. @LuWcmm @Lund_Stem @lunduniversity. Tweets by Filipe Pereira (signed FP) and Malavika Nair (for CFP lab).

◷ Joined June 2016▧ 240 Photos and videos
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 13

Have you read our recent paper? In “Multidimensional Views of Immunotherapy” (@ImmunityCP), I share my perspective on how type 1 conventional dendritic cells (cDC1s) can shape intratumoral lymphoid niches and anti-tumor immunity. Check here: cell.com/immunity/fulltext/S…

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 6

3/3 Ultimately, we aim to determine whether induced imgTLSs can transform the treatment of refractory cancers. We thank our collaborators Dr. Inge Marie Svane and Dr. Göran B. Jönsson, and are grateful to the Swedish Research Council for making this possible. #TLSimmunotherapy

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 6

2/3 We will identify the molecular drivers of imgTLS formation and develop an imgTLS-inducing gene therapy capable of combining dendritic cell-driven immune activation with the generation of these specialized immune hubs.

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 6

1/3 Following our recent Immunity publication, we're excited to announce a new Swedish Research Council grant: “Engineering Immunogenic Tertiary Lymphoid Structures by Tumour-to-Dendritic Cell Reprogramming.” This project will take our discoveries one step further.🙌

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

14) 👥 We are grateful to our collaborators Göran B Jönsson, Anna Darabi and Johan Bengzon, and @AsgardThx for their incredible contributions!

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

13) 📖 This study was led by Ervin Ascic and Camille Chatelain, with contributions from Pereira Lab members.

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

12) Our findings establish tumor-to-cDC1 reprogramming as a strategy to engineer immunogenic tertiary lymphoid structures and may provide a new avenue to overcome immune resistance in low-immunogenic tumors. 🎉

Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

11) Our proposed model: · Tumor-to-cDC1 reprogramming induces mature imgTLSs across cancers · cDC1-like cells orchestrate TLS formation by interacting with T cells · imgTLSs coordinate T-cell and B-cell immunity · Local immune remodeling drives systemic anti-tumor responses

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

10) Remarkably, humoral immunity was also enhanced. imgTLSs supported durable tumor-specific antibody responses, highlighting a role for B-cell immunity in long-term tumor control.

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

9) ImgTLSs promoted systemic immunity beyond the treated tumor. We observed expansion of shared T-cell clonotypes in distant untreated tumors, indicating broad anti-tumor immune responses.

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

8) Migratory DC-LAMP⁺CCR7⁺ cDC1s act as organizers of immune niches enriched for T cells and B cells.

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

7) Spatial transcriptomics and imaging of imgTLSs revealed that DCs acquire conserved spatially restricted resident and migratory signaling programs in TLS-containing tumors. Both proximal and distal DC subsets promote rapid induction of lymphotoxin, TNFα, and CD40.

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

6) How does this happen? Reprogrammed cDC1-like cells interact with T cells through MHC class I and CD40 signaling to drive imgTLS formation.

Post attachment
Pereira Lab avatar
Pereira Lab@CellReproLab·Nov 4

5) Of note: reprogramming cancer cells into cDC1-like cells rapidly induced mature immunogenic TLSs with germinal centers in melanoma, colon, bladder, breast, and pancreatic cancer models. This happened independently of endogenous cDC1s and correlated with long-term survival.

Post attachmentPost attachment